These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 8616080)

  • 1. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
    Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
    Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
    Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F
    Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
    Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
    Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
    Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
    Battelli MG; Buonamici L; Bolognesi A; Stirpe F
    Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
    Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
    Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
    Sforzini S; Bolognesi A; Meazza R; Marciano S; Casalini P; Dürkop H; Tazzari PL; Stein H; Stirpe F; Ferrini S
    Br J Haematol; 1995 Jul; 90(3):572-7. PubMed ID: 7646996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
    Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
    J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
    Bolognesi A; Polito L; Tazzari PL; Lemoli RM; Lubelli C; Fogli M; Boon L; de Boer M; Stirpe F
    Br J Haematol; 2000 Aug; 110(2):351-61. PubMed ID: 10971392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies.
    Bolognesi A; Tazzari PL; Tassi C; Gromo G; Gobbi M; Stirpe F
    Clin Exp Immunol; 1992 Sep; 89(3):341-6. PubMed ID: 1516253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD30 immunotoxins with native and recombinant dianthin 30.
    Bolognesi A; Tazzari PL; Legname G; Olivieri F; Modena D; Conte R; Stirpe F
    Cancer Immunol Immunother; 1995 Feb; 40(2):109-14. PubMed ID: 7882380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.
    Stirpe F; Wawrzynczak EJ; Brown AN; Knyba RE; Watson GJ; Barbieri L; Thorpe PE
    Br J Cancer; 1988 Nov; 58(5):558-61. PubMed ID: 3265330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
    Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
    Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.